E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with metastatic or local recurrenct squamous carcinoma of the head and neck (HNSCC) who have measurable progressive disease after platinum-based radiochemotherapy or recurrence or metastatic progressive disease after first line platinum-based chemotherapy. Failure of at least one line of cisplatin-based therapy and cetuximab is required. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with cancer of the head and neck who have progressive disease after radiochemotherapy or recurrence or metastatic progressive disease after first line chemotherapy. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060121 |
E.1.2 | Term | Squamous cell carcinoma of head and neck |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine the efficacy (progression free rate at day 84 [12 weeks]; PFR) of temsirolimus 25 mg i.v. once weekly in patients with relapsed or recurrent HNSCC after failure of platinum- and cetuximab-based regimens.
|
|
E.2.2 | Secondary objectives of the trial |
- Time to progression (TTP) - The disease control rate (DCR: CR+PR+SD) - The over all survival rate (OS) - Safety and tolerability of temsirolimus (evaluating according to CTC 3.0 criteria) - Evaluation of predictive markers of tumor response in serum and tumor specimen |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Signed written informed consent must be given prior to study inclusion - Histological or cytological confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) - Measurable progressive disease after platinum-based radiochemotherapy or recurrence or metastatic progressive disease after first line platinum-based chemotherapy - Patients with loco-regional recurrence need to be progression free for at least 6 months after platinum-based radiochemotherapy, if locoregional recurrence is the only lesion - Cetuximab must have been included in at least one prior line of therapy - Prior exposure to a taxane is permitted - Disease is not amenable to surgery, radiotherapy or platinum-based chemotherapy - At least one measurable lesion according to RECIST (version 1.0) criteria - Age > 18 years - ECOG performance status 0-2 - Brain metastases require completion of local therapy with discontinuation of steroids prior to start of teatment
|
|
E.4 | Principal exclusion criteria |
- Live expectancy less than 3 months - Anticancer treatment during the last 30 days prior to start of treatment including systemic therapy, radiotherapy or major surgery - Participation in a clinical trial within the last 30 days prior to study treatment - Serious illness or medical condition other than the disease under study - Other malignancies within 3 years, with exception of HNSCC, history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix - Inability to potentially complete follow up and treatment per protocol for psychological, familial, sociological or geographical reasons - Pregnancy or breast feeding - Known allergic/ hypersensitivity reaction to any component of the treatment - Concurrent treatment with oral anticoagulants - Uncontrolled diabetes: fasting serum glucose > 2.0 ULN - Active or uncontrolled infection
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- progressive free rate (PFR) at treatment day 84 (12 weeks) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) time to progression 2) disease control rate 3) overall survival rate 4) safety and tolerablility of temsirolimus 5) evaluation of predictive markers of tumor response in serum and tumor specimen |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) - 5) until end of follow-up period |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |